BSE - Delayed Quote INR

Suven Life Sciences Limited (SUVEN.BO)

Compare
114.50 -9.15 (-7.40%)
At close: 3:41 PM GMT+5:30

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Mr. Venkateswarlu Jasti M.Pharm. M.S. CEO & Director -- -- 1949
Ms. Sudharani Jasti B.Sc. Whole-Time Director 9.99M -- 1954
Mr. Vivek Sharma CPA Executive Chairman -- -- --
Mr. M. Mohan Kumar C.M.A. Chief Financial Officer -- -- --
Mr. Kundan Kumar Jha Company Secretary & Compliance Officer -- -- --
Ms. Kalyani Jasti President of US Operations -- -- 1979

Suven Life Sciences Limited

8-2-334, SDE Serene Chambers
6th Floor Road No.5, Avenue 7 Banjara Hills
Hyderabad, 500034
India
91 40 2354 1142 https://www.suven.com
Sector:?
Healthcare
Full Time Employees:?
141

Description

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

Corporate Governance

Suven Life Sciences Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 2, 2024 at 10:59 AM UTC - November 6, 2024 at 12:00 PM UTC

Suven Life Sciences Limited Earnings Date

Recent Events

February 14, 2019 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers